Adiponectin Inhibits the Production of CXC Receptor 3 Chemokine Ligands in Macrophages and Reduces T-lymphocyte Recruitment in Atherogenesis
Overview
Authors
Affiliations
Obese individuals often have low plasma adiponectin and concomitant chronic inflammation with a predisposition to metabolic and cardiovascular diseases. The present study reports a novel antiinflammatory action of adiponectin in human monocyte-derived macrophages (MPhi) suppressing T-lymphocyte accumulation in atherogenesis. RNA profiling of lipopolysaccharide-stimulated human MPhi identified CXC chemokine ligands (CXCLs), such as IP-10 (interferon [IFN]-inducible protein 10) (CXCL10), I-TAC (IFN-inducible T-cell alpha chemoattractant) (CXCL11), and Mig (monokine induced by IFN-gamma) (CXCL9), T-lymphocyte chemoattractants associated with atherogenesis, among the top 14 transcripts suppressed by adiponectin. Real-time quantitative RT-PCR and ELISA verified that adiponectin inhibited expression of these chemokines at both the mRNA and protein levels in a concentration-dependent manner. Adiponectin reduced the release by lipopolysaccharide-stimulated MPhi of chemoattractant activity for CXC chemokine receptor 3-transfected (receptor for IP-10, Mig, and I-TAC) lymphocytes. Adiponectin decreased lipopolysaccharide-inducible IP-10 promoter activity in promoter-transfected THP-1 MPhi but did not change IP-10 mRNA stability. In lipopolysaccharide-stimulated MPhi, reduction of IFN-beta by adiponectin preceded inhibition of IP-10 mRNA expression. Immunoblot and chromatin immunoprecipitation analyses demonstrated that adiponectin attenuated activation of the transcription factor IFN regulatory factor 3, involved in the MyD88-independent pathway of Toll-like receptor 4 signaling, and subsequent IFN regulatory factor 3 binding to IFN-beta promoter. In vivo studies further demonstrated that apolipoprotein E/adiponectin double-deficient (apoE-/-APN-/-) mice had increased plasma IP-10 levels, accelerated T-lymphocyte accumulation in atheromata, and augmented atherogenesis compared with apoE single-deficient (apoE-/-APN+/+) mice. This study establishes that low levels of adiponectin associated with obesity, the metabolic syndrome, and diabetes favor T-lymphocyte recruitment and contribute to adaptive immune response during atherogenesis.
Duan Y, Liu D, Yu H, Zhang S, Xia Y, Du Z Cell Biosci. 2024; 14(1):126.
PMID: 39354565 PMC: 11443667. DOI: 10.1186/s13578-024-01306-5.
Therapeutic potential of adiponectin in prediabetes: strategies, challenges, and future directions.
Abdalla M Ther Adv Endocrinol Metab. 2024; 15:20420188231222371.
PMID: 38250316 PMC: 10798122. DOI: 10.1177/20420188231222371.
Olivares-Caro L, Nova-Baza D, Radojkovic C, Bustamante L, Duran D, Mennickent D Antioxidants (Basel). 2023; 12(2).
PMID: 36829862 PMC: 9952125. DOI: 10.3390/antiox12020304.
Crosstalk Between Adipose Tissue and the Heart: An Update.
Li C, Sun X, Zhao S, Scherer P J Transl Int Med. 2023; 10(3):219-226.
PMID: 36776231 PMC: 9901553. DOI: 10.2478/jtim-2022-0039.
Johnston E, Abbott R Cells. 2023; 12(3).
PMID: 36766750 PMC: 9913478. DOI: 10.3390/cells12030407.